Medeon Biodesign (ROCO:6499) Cash-to-Debt : 9.54 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medeon Biodesign's cash to debt ratio for the quarter that ended in Mar. 2024 was 9.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Medeon Biodesign could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Medeon Biodesign's Cash-to-Debt or its related term are showing as below:

ROCO:6499' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.44 Med: 75.62 Max: 126178.09
Current: 9.54

During the past 12 years, Medeon Biodesign's highest Cash to Debt Ratio was 126178.09. The lowest was 4.44. And the median was 75.62.

ROCO:6499's Cash-to-Debt is ranked better than
72% of 857 companies
in the Medical Devices & Instruments industry
Industry Median: 1.89 vs ROCO:6499: 9.54

Medeon Biodesign Cash-to-Debt Historical Data

The historical data trend for Medeon Biodesign's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Medeon Biodesign Cash-to-Debt Chart

Medeon Biodesign Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

126,178.09

15.21

4.44

77.71

7.78

Medeon Biodesign Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															7.78	6.14	12.49	11.53	9.54

Competitive Comparison of Medeon Biodesign's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medeon Biodesign's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Cash-to-Debt falls into.

Medeon Biodesign Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Medeon Biodesign's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1547.238	/	(36.686	+	162.224)
	=	7.78

Medeon Biodesign's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1940.451	/	(50.667	+	152.789)
	=	9.54

Medeon Biodesign (ROCO:6499) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Medeon Biodesign Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeon Biodesign (ROCO:6499) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website

http://www.medeonbio.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines